SciSparc Ltd. (SPRC) News
Track canonical SquawkNews coverage tagged to SPRC, SciSparc Ltd.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 16 indexed stories across 12 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
SPRC - SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
SPRC - SciSparc: Subsidiary NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
NEWS | Sep 23, 2026, 12:42 PM UTC
M
SciSparc unit NeuroThera pursues FDA orphan drug designation for adult Tourette
NeuroThera Labs, a SciSparc subsidiary, is pursuing FDA orphan drug designation for an adult Tourette Syndrome treatment and has engaged RK Strategies for government and public affairs support.
GEOPOLITICS | Sep 02, 2026, 12:11 PM UTC
L
SciSparc unit NeuroThera Labs reports SCI-210 autism trial enrollment momentum
SciSparc subsidiary NeuroThera Labs said it has achieved significant enrollment momentum in its SCI-210 autism clinical trial.
EQUITY | Aug 31, 2026, 08:07 PM UTC
L
SciSparc subsidiary NeuroThera reports enrollment momentum in SCI-210 trial
SciSparc says its NeuroThera Labs has achieved significant enrollment momentum in its SCI-210 autism clinical trial.
EQUITY | Aug 31, 2026, 08:03 PM UTC
L
NeuroThera Labs Engages Dr. Reuter Investor Relations
NeuroThera Labs Engages Dr. Reuter Investor Relations
EQUITY | Aug 27, 2026, 12:01 PM UTC
L
SciSparc adds Prof. Carmel Domshlak to scientific advisory board
SciSparc said it is advancing its agentic AI strategy by adding Prof. Carmel Domshlak to its scientific advisory board.
EQUITY | Aug 26, 2026, 12:37 PM UTC
L
SciSparc adds Prof. Carmel Domshlak to advisory board
SciSparc says it is advancing its agentic AI strategy after adding Prof. Carmel Domshlak to its Scientific Advisory Board.
EQUITY | Aug 26, 2026, 12:32 PM UTC
L
SciSparc unit and Clearmind publish U.S. patent application for MDMA-PEA use
SciSparc subsidiary NeuroThera Labs and Clearmind Medicine say the USPTO published a U.S. patent application covering MDMA and N-acylethanolamines, including PEA, for methods of treating PTSD, anxiety and eating disorder
REGULATION | Aug 24, 2026, 12:54 PM UTC
M
SPRC SciSparc advances mdma-N-acylethanolamines IP for PTSD
SPRC SciSparc and NeuroThera/ClearMind collaboration advances mdma-N-acylethanolamines intellectual property for the treatment of PTSD, amid rising U.S. federal support for psychedelic innovation.
REGULATION | Aug 24, 2026, 12:51 PM UTC
M
SPRC unit SciSparc advances PTSD-related MDMA-N-acylethanolamines IP
SPRC, via SciSparc and NeuroThera-Clearmind collaboration, advances intellectual property for MDMA-N-acylethanolamines aimed at treating PTSD.
EQUITY | Aug 24, 2026, 12:51 PM UTC
L
SPRC’s NeuroThera Labs completes C$5.4m financing
SciSparc’s subsidiary NeuroThera Labs completes a C$5.4 million financing, with SciSparc’s stake valued at approximately C$30 million.
EQUITY | Aug 18, 2026, 12:06 PM UTC
L
SPRC Subsidiary Gets Japanese Patent
SPRC's NeuroThera Labs granted Japanese patent for therapeutic combination
EQUITY | Aug 12, 2026, 12:25 PM UTC
M
SciSparc Subsidiary Launches Tourette Syndrome Trial
SciSparc starts phase IIb trial for Tourette treatment
EQUITY | Aug 05, 2026, 12:22 PM UTC
M
SPRC Demonstrates Quantum Workflow
SPRC's subsidiary demonstrates quantum workflow
EQUITY | Jul 31, 2026, 12:20 PM UTC
M
SPRC Advances Quantum Platform
SPRC subsidiary advances quantum platform
EQUITY | Jul 29, 2026, 12:32 PM UTC
L
SPRC Scisparc: neurothera Labs announces initiation of phase iib clinical trial at hannover Medical school in Germany for innovative treatme
SPRC Scisparc: neurothera Labs announces initiation of phase iib clinical trial at hannover Medical school in Germany for innovative treatment of tourette syndrome
EQUITY | Jul 15, 2026, 12:41 PM UTC